GlassScriptPhysician profile
Paul L Mefferd
NPI 1376755538
$3,228.38
in general payments reported to CMS, 2019-2025
40 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $459 · 2021: $1,242 · 2022: $354 · 2023: $160 · 2024: $353 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $537.88 | 2021-2024 | Intellis Adaptivestim |
| Abbvie INC. | $402.30 | 2021-2025 | |
| Medtronic USA, INC. | $249.33 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.63 | 2019-2025 | Relistor |
| Amgen INC. | $196.80 | 2021-2022 | |
| Pfizer INC. | $187.07 | 2019-2025 | |
| Abbott Laboratories | $169.09 | 2020-2025 | Proclaim, Eterna |
| Biohaven Pharmaceuticals, INC. | $119.41 | 2021 | |
| Supernus Pharmaceuticals, INC. | $104.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $68.61 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.36 | 2022 | |
| Redhill Biopharma INC. | $61.70 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $60.60 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $59.12 | 2022-2024 | |
| Spr Therapeutics, INC | $58.15 | 2022-2025 | Sprint Pns System |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mefferd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.